Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome
Open Access
- 18 September 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 35 (6), 1745-1750
- https://doi.org/10.1038/s41375-020-01022-2
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromesHaematologica, 2017
- Toxicity of iron overload and iron overload reduction in the setting of hematopoietic stem cell transplantation for hematologic malignanciesCritical Reviews in Oncology/Hematology, 2017
- New insights into transfusion-related iron toxicity: Implications for the oncologistCritical Reviews in Oncology/Hematology, 2016
- Oxidative stress, redox regulation and diseases of cellular differentiationBiochimica et Biophysica Acta (BBA) - General Subjects, 2014
- Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndromeBlood, 2014
- Identification of erythroferrone as an erythroid regulator of iron metabolismNature Genetics, 2014
- Plasma Levels of Aminothiols, Nitrite, Nitrate, and Malondialdehyde in Myelodysplastic Syndromes in the Context of Clinical Outcomes and as a Consequence of Iron OverloadOxidative Medicine and Cellular Longevity, 2014
- Hepcidin and iron homeostasisBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2012
- Clinical Relevance of Anemia and Transfusion Iron Overload in Myelodysplastic SyndromesHematology, 2008
- Prognostic Factors and Life Expectancy in Myelodysplastic Syndromes Classified According to WHO Criteria: A Basis for Clinical Decision MakingJournal of Clinical Oncology, 2005